Year: 2002
Type: article
Abstract: Cancer primary prevention clinical trials are different from diseasespecific treatment trials.Prevention trials t\ picallv I include participants who are othersk Re healthy, devoid of symptoms and thus require that to\icities or 'ide ci eels trom an inters eritmon be minimal, , require large numbers of subjects to detect a difference between the intervention and control groups.and 3) require long study and lbllos-up periods to detect differences in outcomes related to all-cause survival.cancer-specit mc stirs i sal and qualit\ ot life.SELECT.the Selenium and Vitamin E Cancer Prevention Trial presented here, otters the opportunity to men in Hawaii to part mcipate in a clinical trial and contribute to our scientific understanding and control of prostate cancer.Carcinoma of the prostate is the most comnnion tumor in the Luited States with I 593)0(1 ness cases and 30.20ff deaths expected in 2t)02. in hawaii.estimates for prostate cancer in 2002 are 700 new eases and 100 prostate cancer-related deaths.Histologic evidence of the disease may occur in as litany of 34ff of men in their fifth decade.and tip to 7( P4 of men 50 years of age and older.\\ hile i me in ti ye L'S.men s ill he diagnosed with prostate cancer during his lifetime.onl 3ff of men are expected to die of [he disease, The menu of treatment options for localized prostate cancer includes radical prostatectomy, external-beam radiation therapy.hrachvtherapv.hormonal treatments or surveillance.Issues that contimund the ch nec of ti'eatmcnt include side et'ffcts of treatment.the inability to predict the natural historr of a giveti cancer, and patieiit comorhid conditions that may ultimately affect the patient's likelihood of succumbing to prostate cancer morhidit\ and mortality.The ques tion of \\ hether screening digital m-ectal examination and PSA improve mortal mt\ and morbidit\ awaits the results ol ongoing clinical trials such as the Prostate, lung.Colon, and Osarian PLCO) trial sponsored by the National Cancer Institute.I-losves er, prostate screening appears to have resulted in a substantial stage migration in diagnosed prostate cancer'.to earlier.potentiall cur able stages metastatic prostate cancer at initial diagnosis may become a historical t)jotnote.Factors that increase the risk for prostate cancer include increas ing age.prostate cancer in first degree male relatives, the male hormonal testosteroite nnliett.race and dictar\ tat.Sonic studies a'.'.ocmate increased dietar intake ot Eu its and ecetab e" svi t h a reduced risk of prostate cancer.Although it mar he increasinglr evident that dietary choices play a role in the development of prostate and other cancers.changing patterns oi dietarr behas or and life-long inter\ ention niakes this stiategy difficult in practice.Since the I )X0".. ehemopres ention.the use nt natural or '.vnthetic substances to reduce the risk of
Source: PubMed
Author: James Tom
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2406882861